NCT00676299: A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. |
|
|
| Completed | 1 | 19 | US | JNJ-26483327 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen Pharmaceutica N.V., Belgium | Protein Kinase Inhibitors, Antineoplastic Protocols, Clinical Trial, Phase 1, Maximum Tolerated Dose, Pharmacokinetics, Advanced Malignancies, Solid Malignancies | | 07/08 | | |
